Clinical trials: gemcitabine hydrochloride
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreatic Cancer
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally…
- Trial name
- NCT06346808
- Testing
- Oncolytic virus Plus Anti-PD1 and Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Radical Cystectomy, Urothelial Carcinoma
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC…
- Trial name
- NCT05723991
- Testing
- Disitamab Vedotin and Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Chunguang yang (101937)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, oxaliplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00304135
- Testing
- cisplatin, gemcitabine hydrochloride, oxaliplatin
- Where
- 20 sites in France
- Volunteers
- 34 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hodgkin Lymphoma, Non-hodgkin Lymphoma
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
- Trial name
- NCT03602131
- Testing
- Chidamide, Cladribine, gemcitabine
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
DLBCL - Diffuse Large B Cell Lymphoma
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R …
- Trial name
- NCT07389356
- Testing
- Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Neoplasms Pancreatic
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG.
- Trial name
- NCT04151277
- Testing
- FOLFOX-A, Gemcitabe and Abraxane, G-CSF
- Where
- 30 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Judith Dixon-Hughes
Metastatic Sarcoma
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.
- Trial name
- NCT02448537
- Testing
- PM01183, Doxorubicin, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Non-Small-Cell Lung Carcinoma
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different…
- Trial name
- NCT00148395
- Testing
- Gemcitabine, Navelbine, Carboplatin
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Metastatic Breast Cancer
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06383767
- Testing
- ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Cancer
A Phase II Study of Locally Advanced Pancreatic Cancer
The primary end point is to evaluate the 9-month progression free survival rate and safety profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic…
- Trial name
- NCT01867892
- Testing
- ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT, ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
- Volunteers
- 86 people
- Sponsor
- National Health Research Institutes, Taiwan
Metastatic Adenocarcinoma of the Pancreas
Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase 1b, Open-Label, Safety, Pharmacokinetic, and Pharmacodynamic Study of an Anti-super-enhancer Minnelide Once a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with…
- Trial name
- NCT05557851
- Testing
- Minnelide
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Minneamrita Therapeutics LLC
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Pancreas Cancer
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma
- Trial name
- AA NABPLAGEM (NCT03410030)
- Testing
- High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- HonorHealth Research Institute
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens.
- Trial name
- BEACON (NCT01492101)
- Testing
- NKTR-102, Treatment of Physician's Choice (TPC)
- Where
- 153 sites in United States, Belgium and 9 more
- Volunteers
- 852 people
- Sponsor
- Nektar Therapeutics
Carcinoma, Non-Small-Cell Lung
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial
The purposes of this study are to determine: 1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2.
- Trial name
- NCT00061451
- Testing
- Pemetrexed, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Pancreatic Neoplasm
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with…
- Trial name
- VANILLA (NCT00574275)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Gemcitabine
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Pancreatic Cancer
Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer
Patients with resected pancreatic cancer who fulfill the selection criteria will be randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine, the standard arm, or FOLFOXIRI (the combination of…
- Trial name
- GIP-2 (NCT02355119)
- Testing
- FOLFOXIRI, Gemcitabine
- Where
- Italy
- Volunteers
- 310 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Pancreatic Cancer
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
This is an open multicenter randomized phase I/II study. The main purpose with this study is to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus given biweekly to patients with local advanced…
- Trial name
- NCT01042028
- Testing
- Everolimus, Cetuximab, Irinotecan, Capecitabine, Oxaliplatine
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Per Pfeiffer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.